Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02440568 · ClinicalTrials.gov registry record · Phase 1
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02440568 is a Phase 1 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 22 participants.
The verdict
NCT02440568, a Phase 1 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a dose escalation study to evaluate Omacetaxine when given in combination with a standard induction regimen of "7+3" (cytarabine for Days 1-7 and Idarubicin for Days 1-3) in patients with newly diagnosed acute myelogenous leukemia (AML).
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Omacetaxine mepesuccinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-06-05 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02440568
The ClinicalTrials.gov registry entry for NCT02440568 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02440568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02440568 about?
NCT02440568 is a clinical study titled "AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients". This is a dose escalation study to evaluate Omacetaxine when given in combination with a standard induction regimen of "7+3" (cytarabine for Days 1-7 and Idarubicin for Days 1-3) in patients with newly diagnosed acute myelogenous leukemia (AML).
What is the current status of trial NCT02440568?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-06-05. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT02440568?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Omacetaxine mepesuccinate (DRUG).
Who is sponsoring clinical trial NCT02440568?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.